Loading...
An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies
Moxetumomab pasudotox (HA22) is a recombinant immunotoxin, now in clinical trials, that combines an anti-CD22-Fv with a 38-kDa fragment of Pseudomonas exotoxin A. To produce a less immunogenic molecule without reducing the half-life in circulation, we constructed LMB11 combining an anti-CD22 Fab wit...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4182334/ https://ncbi.nlm.nih.gov/pubmed/25127689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2014.06.014 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|